Researchers funded by the Canadian Cancer Society have discovered eight similar genes that, when mutated, appear to be responsible for medulloblastoma – the most common of childhood brain cancers. The findings are published today in the online edition of the journal Nature Genetics.
"This discovery is very promising and may help researchers develop better, more targeted treatments so that more of these children will survive and fewer will suffer debilitating side effects," says Dr. Christine Williams, Director of Research Programs, Canadian Cancer Society Research Institute.
Dr. Michael Taylor, who has a $600,000 research grant from the Canadian Cancer Society, led the study: "When these eight genes are functioning normally, we believe their role is to make a protein which tells the developing brain when it's time to stop growing. But when the genes are mutated, the brain may continue to grow out of control, leading to cancer.
"Drugs are already being developed that target these types of proteins," he says. "Our hope is that some of these drugs may be adapted and used effectively to treat medulloblastomas." Dr. Taylor is a pediatric brain surgeon at Toronto's Hospital for Sick Children:
In the study, the largest of its kind, researchers looked at more than 200 tumour samples. The samples came from children in countries all over the world including Canada, the US, England, Poland and Saudi Arabia. Paul Northcott, a PhD student in Dr Taylor's lab, analyzed and interpreted all the data over a period of 3 ½ years. "We've learned more from this study about the genetic basis of this disease than from any other previous study," Northcott says. The gene mutations they found had not been suspected as culprits in cancer formation.
About 250 Canadian children are diagnosed with various types of brain cancer every year. About 70 per cent of these survive. Brain tumours are the leading cause of childhood cancer deaths. The most common childhood brain cancer is medulloblastoma – a tumour that occurs at the back of the brain in the cerebellum. It is primarily a disease of very young children and is particularly deadly among babies under 18 months of age. In Canada, about 40 children are diagnosed with medulloblastoma every year and half of these will survive.
Many survivors experience serious physical and neurological problems from the disease itself and from the effects of very aggressive treatments on the developing brain. Treatments include surgery, radiation and chemotherapy.
Christine Harminc | EurekAlert!
New image of a cancer-related enzyme in action helps explain gene regulation
05.06.2020 | Penn State
Protecting the Neuronal Architecture
05.06.2020 | Universität Heidelberg
Humans rely dominantly on their eyesight. Losing vision means not being able to read, recognize faces or find objects. Macular degeneration is one of the major...
In meningococci, the RNA-binding protein ProQ plays a major role. Together with RNA molecules, it regulates processes that are important for pathogenic properties of the bacteria.
Meningococci are bacteria that can cause life-threatening meningitis and sepsis. These pathogens use a small protein with a large impact: The RNA-binding...
An analysis of more than 200,000 spiral galaxies has revealed unexpected links between spin directions of galaxies, and the structure formed by these links...
Two prominent X-ray emission lines of highly charged iron have puzzled astrophysicists for decades: their measured and calculated brightness ratios always disagree. This hinders good determinations of plasma temperatures and densities. New, careful high-precision measurements, together with top-level calculations now exclude all hitherto proposed explanations for this discrepancy, and thus deepen the problem.
Hot astrophysical plasmas fill the intergalactic space, and brightly shine in stellar coronae, active galactic nuclei, and supernova remnants. They contain...
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
05.06.2020 | Life Sciences
05.06.2020 | Physics and Astronomy
05.06.2020 | Life Sciences